Shohei Myoba
Ayase, 2521123, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Clinical implications of serum GDF15 propeptide as a biomarker for bone metastasis across common solid tumors: a real-world multi-institutional study.
Journal: Biomarker research
Published: April 29, 2026
Tissue factor pathway inhibitor 2 (TFPI2) is a potential serum biomarker for clear cell renal carcinoma.
Journal: Scientific reports
Published: August 30, 2024
Tissue factor pathway inhibitor-2 inhibits integrin β1 activation and focal adhesion formation and suppresses peritoneal ovarian cancer dissemination in mice.
Journal: Biochemical and biophysical research communications
Published: July 12, 2024
Tissue factor pathway inhibitor 2: A potential diagnostic marker for discriminating benign from malignant ovarian tumors.
Journal: The journal of obstetrics and gynaecology research
Published: May 04, 2022
Tissue Factor Pathway Inhibitor 2: A Novel Biomarker for Predicting Asymptomatic Venous Thromboembolism in Patients with Epithelial Ovarian Cancer.
Journal: Gynecologic and obstetric investigation
Published: January 26, 2022
Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results.
Journal: Molecular and clinical oncology
Published: November 11, 2021
Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
Journal: Oncology reports
Published: September 30, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026